Published in Allergy on September 07, 2010
Treatment of chronic spontaneous urticaria. Allergy Asthma Immunol Res (2012) 1.32
Effects of omalizumab treatment in patients with refractory chronic urticaria. Allergy Asthma Immunol Res (2012) 1.08
Omalizumab for chronic urticaria: a case series and overview of the literature. Case Rep Dermatol (2012) 1.03
Omalizumab in treatment-resistant chronic spontaneous urticaria. Indian J Dermatol (2011) 0.87
Anti-IgE Treatment for Disorders Other Than Asthma. Front Med (Lausanne) (2017) 0.75
Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature (2000) 5.86
EAACI/GA(2)LEN/EDF/WAO guideline: definition, classification and diagnosis of urticaria. Allergy (2009) 4.10
EAACI/GA(2)LEN/EDF/WAO guideline: management of urticaria. Allergy (2009) 3.86
CENP-C, an autoantigen in scleroderma, is a component of the human inner kinetochore plate. Cell (1992) 3.70
The EAACI/GA(2) LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. Allergy (2014) 3.10
A comprehensive guide for the recognition and classification of distinct stages of hair follicle morphogenesis. J Invest Dermatol (1999) 2.92
Allergic Rhinitis and its Impact on Asthma (ARIA): achievements in 10 years and future needs. J Allergy Clin Immunol (2012) 2.17
Home versus hospital deliveries: follow up study of matched pairs for procedures and outcome. Zurich Study Team. BMJ (1996) 2.10
Mast cells as sentinels of innate immunity. Curr Opin Immunol (1999) 1.85
Factors responsible for differences between asymptomatic subjects and patients presenting an IgE sensitization to allergens. A GA2LEN project. Allergy (2006) 1.84
Impaired mast cell-dependent natural immunity in complement C3-deficient mice. Nature (1997) 1.78
EAACI/GA(2)LEN task force consensus report: the autologous serum skin test in urticaria. Allergy (2009) 1.65
Autologous whole blood injections to patients with chronic urticaria and a positive autologous serum skin test: a placebo-controlled trial. Dermatology (2006) 1.65
Molecular cloning, chromosome mapping and characterization of UBQLN3 a testis-specific gene that contains an ubiquitin-like domain. Gene (2000) 1.57
How to assess disease activity in patients with chronic urticaria? Allergy (2008) 1.55
EAACI/GA2LEN/EDF guideline: definition, classification and diagnosis of urticaria. Allergy (2006) 1.55
Embolization of biologic glue during repair of aortic dissection. Ann Thorac Surg (1995) 1.52
How best to fight that nasty itch - from new insights into the neuroimmunological, neuroendocrine, and neurophysiological bases of pruritus to novel therapeutic approaches. Exp Dermatol (2005) 1.51
Control of murine hair follicle regression (catagen) by TGF-beta1 in vivo. FASEB J (2000) 1.48
[Anaphylaxis after vaccination due to hypersensitivity to gelatin]. Klin Padiatr (2006) 1.44
A soluble class II cytokine receptor, IL-22RA2, is a naturally occurring IL-22 antagonist. Proc Natl Acad Sci U S A (2001) 1.43
Risk of first-generation H(1)-antihistamines: a GA(2)LEN position paper. Allergy (2010) 1.42
Fatal recurrent subarachnoid hemorrhage after complete endovascular aneurysm occlusion. AJNR Am J Neuroradiol (2006) 1.40
The definition and diagnostic testing of physical and cholinergic urticarias--EAACI/GA2LEN/EDF/UNEV consensus panel recommendations. Allergy (2009) 1.39
Schnitzler's syndrome: diagnosis, treatment, and follow-up. Allergy (2013) 1.35
NMR solution structure of a complex of calmodulin with a binding peptide of the Ca2+ pump. Biochemistry (1999) 1.33
Identification of a novel class of genomic DNA-binding sites suggests a mechanism for selectivity in target gene activation by the tumor suppressor protein p53. Genes Dev (1998) 1.31
p53 is essential for chemotherapy-induced hair loss. Cancer Res (2000) 1.29
EAACI/GA2LEN/EDF guideline: management of urticaria. Allergy (2006) 1.28
Melanogenesis during the anagen-catagen-telogen transformation of the murine hair cycle. J Invest Dermatol (1994) 1.27
A simultaneous (15)N, (1)H- and (13)C, (1)H-HSQC with sensitivity enhancement and a heteronuclear gradient echo. J Biomol NMR (1995) 1.25
Impaired mast cell development and innate immunity in Mac-1 (CD11b/CD18, CR3)-deficient mice. J Immunol (1998) 1.25
Quality of life in patients with chronic urticaria is differentially impaired and determined by psychiatric comorbidity. Br J Dermatol (2006) 1.24
Characterization of functional vanilloid receptors expressed by mast cells. Blood (1998) 1.21
p53 Involvement in the control of murine hair follicle regression. Am J Pathol (2001) 1.19
Methods report on the development of the 2013 revision and update of the EAACI/GA2 LEN/EDF/WAO guideline for the definition, classification, diagnosis, and management of urticaria. Allergy (2014) 1.16
Re-engineering the toilet for sustainable waste water management. Environ Sci Technol (2001) 1.14
Rupatadine in allergic rhinitis and chronic urticaria. Allergy (2008) 1.13
Epidemiology of urticaria: a representative cross-sectional population survey. Clin Exp Dermatol (2010) 1.12
Antibacterial effects of cefroxadine, cephalexin and cephradine in a new in vitro pharmacokinetic model. J Antibiot (Tokyo) (1982) 1.11
Up-dosing with bilastine results in improved effectiveness in cold contact urticaria. Allergy (2013) 1.09
Polyspecific, antiviral immune response distinguishes multiple sclerosis and neuromyelitis optica. J Neurol Neurosurg Psychiatry (2008) 1.08
The German version of the Chronic Urticaria Quality-of-Life Questionnaire: factor analysis, validation, and initial clinical findings. Allergy (2009) 1.07
Treatment of skin swellings with C1-inhibitor concentrate in patients with hereditary angio-oedema. Allergy (2008) 1.06
Mast cell involvement in murine hair growth. Dev Biol (1994) 1.06
Successful treatment of cholinergic urticaria with anti-immunoglobulin E therapy. Allergy (2008) 1.04
Cytotoxic drug-induced, p53-mediated upregulation of caspase-8 in tumor cells. Oncogene (2007) 1.04
Mast cells as initiators of immunity and host defense. Exp Dermatol (2001) 1.02
Effectiveness of a procalcitonin algorithm to guide antibiotic therapy in respiratory tract infections outside of study conditions: a post-study survey. Eur J Clin Microbiol Infect Dis (2009) 1.01
Matrix metalloproteinase-9: a novel biomarker for monitoring disease activity in patients with chronic urticaria patients? Allergy (2009) 1.00
Potential immunocompetence of proteolytic fragments produced by proteasomes before evolution of the vertebrate immune system. J Exp Med (1997) 1.00
PLUSH TACSY: Homonuclear planar TACSY with two-band selective shaped pulses applied to C(α),C' transfer and C (β),C (aromatic) correlations. J Biomol NMR (1996) 0.99
A role for CD21/CD35 and CD19 in responses to acute septic peritonitis: a potential mechanism for mast cell activation. J Immunol (2000) 0.99
Recommendations for assessing patient-reported outcomes and health-related quality of life in clinical trials on allergy: a GA(2)LEN taskforce position paper. Allergy (2009) 0.98
Improved neonatal survival following multiple doses of bovine surfactant in very premature neonates at risk for respiratory distress syndrome. Pediatrics (1991) 0.98
Specific recommendations for PROs and HRQoL assessment in allergic rhinitis and/or asthma: a GA(2)LEN taskforce position paper. Allergy (2010) 0.97
Acquired cold urticaria: clinical picture and update on diagnosis and treatment. Clin Exp Dermatol (2007) 0.97
The role of innate immunity in asthma: leads and lessons from mouse models. Allergy (2007) 0.96
Severe chronic allergic (and related) diseases: a uniform approach--a MeDALL--GA2LEN--ARIA position paper. Int Arch Allergy Immunol (2012) 0.96
Pattern analysis of human cutaneous mast cell populations by total body surface mapping. Br J Dermatol (2003) 0.95
EAACI taskforce position paper: evidence for autoimmune urticaria and proposal for defining diagnostic criteria. Allergy (2012) 0.95
Cyclosporin A pharmacokinetics and efficacy in the treatment of atopic dermatitis in dogs. J Vet Pharmacol Ther (2004) 0.94
Planar embryos have poor prognosis in terms of blastocyst formation and implantation. Reprod Biomed Online (2012) 0.94
The use of a responder analysis to identify clinically meaningful differences in chronic urticaria patients following placebo- controlled treatment with rupatadine 10 and 20 mg. J Eur Acad Dermatol Venereol (2009) 0.94
[Autoreactive urticaria and autoimmune urticaria]. Hautarzt (2004) 0.93
Hair cycle-dependent changes in adrenergic skin innervation, and hair growth modulation by adrenergic drugs. J Invest Dermatol (1999) 0.93
Coccidioidomycosis in Tulare County, California, 1991: reemergence of an endemic disease. J Med Vet Mycol (1998) 0.92
A novel, simple, validated and reproducible instrument for assessing provocation threshold levels in patients with symptomatic dermographism. Clin Exp Dermatol (2013) 0.92
Bortezomib and dexamethasone consolidation following risk-adapted melphalan and stem cell transplantation for patients with newly diagnosed light-chain amyloidosis. Leukemia (2012) 0.92
Screening for hemochromatosis and iron deficiency in employees and primary care patients in Western Germany. Ann Intern Med (1998) 0.92
Comparison of the efficacy of levocetirizine 5 mg and desloratadine 5 mg in chronic idiopathic urticaria patients. Allergy (2008) 0.92
Successful treatment of solar urticaria with anti-immunoglobulin E therapy. Allergy (2008) 0.91
Substance P stimulates murine epidermal keratinocyte proliferation and dermal mast cell degranulation in situ. Arch Dermatol Res (1995) 0.91
Cross-correlated relaxation for the measurement of angles between tensorial interactions. J Magn Reson (2000) 0.90
A simple immunofluorescence technique for simultaneous visualization of mast cells and nerve fibers reveals selectivity and hair cycle--dependent changes in mast cell--nerve fiber contacts in murine skin. Arch Dermatol Res (1997) 0.90
Development and construct validation of the angioedema quality of life questionnaire. Allergy (2012) 0.90
[Scale construction of the German version of the Comprehensive Psychopathological Rating Scale (CPRS)]. Int Pharmacopsychiatry (1982) 0.90
Benign biliary obstruction: is treatment with the Wallstent advisable? Radiology (1996) 0.90
New topics in bradykinin research. Allergy (2011) 0.90
Prevention of signs and symptoms of dermographic urticaria by single-dose ebastine 20 mg. Clin Exp Dermatol (2009) 0.90
Modeling the atomic structure of an amorphous NiZr(3) alloy by anomalous wide angle x-ray scattering and reverse Monte Carlo simulation. J Phys Condens Matter (2008) 0.90
Sleep and allergic rhinitis. J Investig Allergol Clin Immunol (2008) 0.90
Murine skin as a target for melatonin bioregulation. Exp Dermatol (1994) 0.89
Who is really in control of skin immunity under physiological circumstances - lymphocytes, dendritic cells or keratinocytes? Exp Dermatol (2006) 0.89
Topical sodium cromoglicate relieves allergen- and histamine-induced dermal pruritus. Br J Dermatol (2009) 0.89